Progen gets in synth

By Dylan Bushell-Embling
Wednesday, 02 July, 2008

Brisbane biotech Progen Pharmaceuticals (ASX: PGL) has spun out its manufacturing business into a wholly-owned subsidiary.

The new subsidiary will be called PharmaSynth, and will be responsible for completing Progen's PI-88 manufacturing process.

It will also offer process development and manufacturing services to the biotechnology industry.

Progen's former director of manufacturing operations, Les Tillack, is the new company's CEO.

Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...

SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...

Researchers have developed a biodegradable smart patch that detects pressure changes and releases...

Content from other channels on our network

Tiny chip may cut AI's growing energy demands

Registrations now open for Clean Up Australia Day 2027

Tilt Renewables awarded five-star rating

"Solar tsunami" may hit businesses as installers go broke

Tiny molecule 'superhighways' to improve industrial processing

Smart bedding targets falls risk in aged care

Calvary confirms some services across two hospitals "will not be offered"

Opinion: Beyond connectivity — making health data meaningful across systems

Winning healthcare equipment tenders: why having the best product is no longer enough

Optimising connectivity: Peninsula University Hospital

pladis program plans to help with a snacking reshape

Food safety testing hub opens in Melbourne

Contamination detection solutions for the food manufacturing industry

Six on the shelf: diverse new food products in November

tna's food packaging solution wins gold at the Good Design Awards 2026